Marker Therapeutics (MRKR) Interest & Investment Income (2014 - 2026)
Marker Therapeutics (MRKR) posted quarterly Interest & Investment Income of $132889.0 for Q1 2026, down 18.22% year-over-year from $162489.0 in Q1 2025, and down 19.77% quarter-over-quarter from $165628.0 in Q4 2025.
Marker Therapeutics (MRKR) Interest & Investment Income (2014 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Interest & Investment Income for 10 consecutive years, with $132889.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 18.22% year-over-year to $132889.0; the TTM figure through Mar 2026 stood at $564606.0 (up 27.36% YoY), while the FY2025 annual figure was $594206.0, up 35.97% from the prior year.
- Interest & Investment Income declined to $132889.0 in Q1 2026 per MRKR's latest filing, from $165628.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $218085.0 in Q3 2023 and bottomed at $3117.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $114783.9 across 5 years, with a median of $115388.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 12510.62% — and 2024, when it slumped 63.37%.
- Marker Therapeutics' Interest & Investment Income stood at $109410.0 in 2022, then soared by 84.02% to $201339.0 in 2023, then plunged by 63.37% to $73746.0 in 2024, then surged by 124.59% to $165628.0 in 2025, then dropped by 19.77% to $132889.0 in 2026.
- Business Quant data shows MRKR's Interest & Investment Income at $132889.0 in Q1 2026, $165628.0 in Q4 2025, and $138064.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | 112,558.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132,889.00 |
| Dec 31, 2025 | 165,628.00 |
| Sep 30, 2025 | 138,064.00 |
| Jun 30, 2025 | 128,025.00 |
| Mar 31, 2025 | 162,489.00 |
| Dec 31, 2024 | 73,746.00 |
| Sep 30, 2024 | 91,681.00 |
| Jun 30, 2024 | 115,388.00 |
| Mar 31, 2024 | 156,195.00 |
| Dec 31, 2023 | 201,339.00 |
| Sep 30, 2023 | 218,085.00 |
| Jun 30, 2023 | 35,080.00 |
| Mar 31, 2023 | 84,654.00 |
| Dec 31, 2022 | 109,410.00 |
| Sep 30, 2022 | 99,750.00 |
| Jun 30, 2022 | 35,786.00 |
| Mar 31, 2022 | 3,117.00 |
| Dec 31, 2021 | 969.00 |
| Sep 30, 2021 | 791.00 |
| Jun 30, 2021 | 2,403.00 |